These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38579726)

  • 1. Shifting the landscape: The role of IDH inhibitors in glioma cell fate.
    Giacobetti SA; Fine HA
    Cancer Cell; 2024 May; 42(5):741-743. PubMed ID: 38579726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
    Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
    Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
    Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
    Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH Inhibitors Target Common Glioma Mutation.
    Cancer Discov; 2019 Aug; 9(8):992. PubMed ID: 31217295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
    Waitkus MS; Yan H
    Clin Cancer Res; 2021 Jan; 27(2):383-388. PubMed ID: 32883741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
    Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
    Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas.
    Schiff D
    N Engl J Med; 2023 Aug; 389(7):653-654. PubMed ID: 37585632
    [No Abstract]   [Full Text] [Related]  

  • 13. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.
    Kotecha R; Schiff D; Chakravarti A; Fleming JL; Brown PD; Puduvalli VK; Vogelbaum MA; Gondi V; Gallus M; Okada H; Mehta MP
    J Clin Oncol; 2024 Jul; 42(21):2588-2598. PubMed ID: 38833641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
    Wirthschaft P; Bode J; Simon AEM; Hoffmann E; van Laack R; Krüwel T; Dietrich F; Bucher D; Hahn A; Sahm F; Breckwoldt MO; Kurz FT; Hielscher T; Fischer B; Dross N; Ruiz de Almodovar C; von Deimling A; Herold-Mende C; Plass C; Boulant S; Wiestler B; Reifenberger G; Lichter P; Wick W; Tews B
    Int J Cancer; 2018 Sep; 143(5):1176-1187. PubMed ID: 29582423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma Response to IDH Inhibition: Real-World Experience.
    Lukas RV; Horbinski C
    Clin Cancer Res; 2023 Dec; 29(23):4709-4710. PubMed ID: 37738033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
    Silvani A; Franceschi E
    Tumori; 2024 Jun; 110(3):160-161. PubMed ID: 38166539
    [No Abstract]   [Full Text] [Related]  

  • 19. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting IDH in Low-Grade Glioma.
    Claus EB; Verhaak RGW
    N Engl J Med; 2023 Aug; 389(7):655-659. PubMed ID: 37585633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.